ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at

Stock News for Gilead Sciences (GILD)
11/27/201514:13:02Giving Thanks, Healthcare Style
11/27/201507:20:035 Dividend Stocks to Buy in December
11/26/201509:03:02Gilead Sciences Grabs 4 Regulatory Wins -- but Does It Matter?
11/25/201514:23:49Statement of Changes in Beneficial Ownership (4)
11/25/201514:22:53Statement of Changes in Beneficial Ownership (4)
11/24/201517:00:00Gilead Sciences to Present at Two Upcoming Investor Conferences...
11/24/201510:24:00Europäische Kommission erteilt Marktzulassung für das Einzeltablettenregime G...
11/24/201508:38:03Healthcare's Greatest Dividend Stocks
11/24/201506:00:00La Commission européenne accorde une autorisation de mise sur...
11/23/201521:46:00La Commissione Europea rilascia l'autorizzazione alla commercializzazione...
11/23/201510:01:03Can Merck & Co. Take Down Gilead Sciences?
11/23/201506:35:00European Commission Grants Marketing Authorization for Gilead’s S...
11/21/201509:04:08Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
11/20/201510:07:58Confidential Treatment Order (ct Order)
11/18/201512:33:49Statement of Changes in Beneficial Ownership (4)
11/18/201511:45:02This Just In: Upgrades and Downgrades
11/17/201511:53:00Le Zydelig® de Gilead, combiné à la bendamustine et au rituximab, dé...
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations